Torigen Pharmaceuticals and VerticalVet Enter into Preferred Partnership

FARMINGTON, CONN. (PRWEB) DECEMBER 08, 2022

Torigen Pharmaceuticals, Inc (Farmington, CT), an animal health biologics company, announced today that they have entered into a Preferred Partnership Agreement with VerticalVet, LLC (Cornelius, NC) to provide their 2,000+ clinic Group Purchasing Organization with access to Torigen. VerticalVet provides independent veterinary owners, practice managers, and technicians access to customized best practices education, real-time data insights, simplified marketing automation, and tailored partner solutions, such as Torigen’s Experimental Autologous Prescription Product.

This partnership will expand Torigen’s ability to deliver innovative companion animal cancer treatments to a larger patient population. Torigen offers experimental autologous cancer immunotherapy created from a surgically resected portion of tumor tissue that can be administered by both General Practitioners and Veterinary Oncologists. The combination of Torigen’s innovative products and VerticalVet’s vast network will allow more clinicians to be part of the veterinary oncology solution and provide more cancer treatment options to fight this devastating diagnosis.

“We are excited to partner with VerticalVet’s 2,000 veterinary hospitals nationwide,” says Ashley Kalinauskas, CEO and Co-Founder of Torigen Pharmaceuticals. “We believe that Torigen’s innovative cancer therapeutics and our diagnostic partnerships can provide more affordable and accessible treatment options to companion animal cancer patients.”

Read the full release here>>